NCT00317772 2022-02-07
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
6 trialsNCT00027690 2019-07-23
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023699 2013-06-24
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049556 2013-06-20
Gefitinib in Treating Patients With Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181688 2012-12-05
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00189358 2010-07-20
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
AGO Study Group
Phase 2 Completed